Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVIR

Atea Pharmaceuticals Inc

4.70

Jul 14 • 03:59PM ET -0.04 (-0.84%)

4.70

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Today, 7:05 AMAtea Pharmaceuticals starts first-in-human Phase 1 trial of oral antiviral AT-587 for hepatitis E virus infection

Peers: INCY BMRN VKTX KRYS KYMR NUVL RYTM AXSM MDGL NBIX

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAS DFMC IWC

Scroll to Statements

Index	RUT
Market Cap	376.13M
Enterprise Value	120.75M
Income	-169.52M
Sales	0.00M
Book/sh	2.92
Cash/sh	3.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Oct 30, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.61
P/C	1.47
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.89
Current Ratio	7.89
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.12
EPS next Y	-1.39
EPS next Q	-0.56
EPS this Y	0.77%
EPS next Y	28.05%
EPS next 5Y	21.13%
EPS past 3/5Y	-11.75% -71.02%
Sales past 3/5Y	- -
EPS Y/Y TTM	-28.75%
Sales Y/Y TTM	-
EPS Q/Q	-42.59%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-2.70% -

Insider Own	20.86%
Insider Trans	0.04%
Inst Own	72.35%
Inst Trans	4.95%
ROA	-47.95%
ROE	-52.58%
ROIC	-72.53%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.72%
SMA50	0.93%
SMA200	10.95%
Trades

Shs Outstand	80.03M
Shs Float	63.33M
Short Float	11.04%
Short Ratio	21.09
Short Interest	6.99M
52W High	6.45 -27.13%
52W Low	2.78 69.06%
Volatility	5.59% 4.78%
ATR (14)	0.23
RSI (14)	50.80
Beta	0.30
Rel Volume	1.03
Avg Volume	331.49K
Volume	341,636

Perf Week	-3.69%
Perf Month	7.80%
Perf Quarter	-17.69%
Perf Half Y	36.23%
Perf YTD	31.65%
Perf Year	25.00%
Perf 3Y	29.12%
Perf 5Y	-79.50%
Perf 10Y	-
Recom	1.67
Target Price	8.67
Prev Close	4.74
Price	4.70
Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$2 → $6.88
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$14 → $7
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral	$61 → $16
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$55
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	William Blair	Outperform	$60
Nov-24-20	Initiated	Morgan Stanley	Overweight	$49
Nov-24-20	Initiated	JP Morgan	Overweight	$45

Today 07:00AM	Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus (GlobeNewswire)
Jun-25-26 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
May-27-26 07:00AM	Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 (GlobeNewswire)
May-13-26 08:30AM	Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby) -16.91%
07:00AM	Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline (GlobeNewswire)
01:01AM	Loading…
01:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
May-12-26 04:05PM	Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-05-26 07:00AM	Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 (GlobeNewswire)
Mar-06-26 08:30AM	Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) +11.13%
12:02AM	Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ... (GuruFocus.com)
Mar-05-26 06:47PM	Atea Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +6.43%
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 (GlobeNewswire)
Jan-19-26 11:19AM	JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens (Pharmaceutical Technology)
02:32PM	Loading…
Jan-15-26 02:32PM	Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference (MarketBeat)
Jan-09-26 07:17AM	Atea Pharmaceuticals to highlight strategic priorities for FY26 (TipRanks)
Jan-08-26 07:00AM	Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-26 07:00AM	Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-25 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
Dec-02-25 04:46PM	ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman (Exec Edge)
Nov-19-25 08:02PM	Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... (GuruFocus.com)
07:00AM	Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -12.57%
Nov-07-25 08:00AM	Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 (GlobeNewswire)
Nov-05-25 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 (GlobeNewswire)
Oct-22-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 (GlobeNewswire)
Sep-02-25 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-07-25 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Jul-31-25 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 (GlobeNewswire)
Jun-24-25 07:00AM	Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America (GlobeNewswire)
May-12-25 04:11PM	Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.82% -11.15%
May-07-25 07:00AM	Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 (GlobeNewswire)
May-01-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 (GlobeNewswire)
Apr-23-25 07:00AM	Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 (GlobeNewswire)
Apr-17-25 07:00AM	Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire)
Apr-09-25 07:00AM	Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
Mar-26-25 01:58PM	Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value (GlobeNewswire)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-21-25 05:54PM	Atea Pharmaceuticals Issues Statement Regarding Director Nominations (GlobeNewswire)
08:25AM	Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory (InsiderMonkey)
Mar-19-25 07:00AM	Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 (GlobeNewswire)
Mar-07-25 12:46PM	Q4 2024 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:17AM	Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ... (GuruFocus.com)
Mar-06-25 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-13-25 07:00AM	Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 07:00AM	Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 05:05PM	Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process (Business Wire)
Dec-16-24 05:00AM	Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships (GlobeNewswire) +5.80%
Dec-05-24 07:06AM	Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir (TipRanks) -5.94%
Dec-04-24 03:14PM	After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study (Benzinga) -10.49%
07:00AM	Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) (GlobeNewswire)
06:09AM	Atea plans Phase 3 study for hepatitis C drug after mid-stage results (BioPharma Dive)
Nov-26-24 07:00AM	Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-22-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-15-24 11:00AM	Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Nov-11-24 08:01PM	Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-07-24 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (GlobeNewswire)
Oct-30-24 07:00AM	Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Oct-16-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks) +6.20%
Oct-09-24 05:19PM	Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Oct-04-24 09:35AM	Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-30-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-13-24 02:53PM	Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus (Benzinga) +5.45%
07:00AM	Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 (GlobeNewswire)
Aug-28-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks)
07:00AM	Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway (GlobeNewswire)
Aug-12-24 12:00PM	All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy (Zacks)
09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-07-24 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.03%
Jul-31-24 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.04%
May-29-24 07:00AM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-24 07:00AM	Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.82%
May-15-24 09:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com) -6.31%
May-14-24 04:05PM	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 07:00AM	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 (GlobeNewswire)
Mar-27-24 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients (GlobeNewswire) +6.10%
Feb-29-24 10:03AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:58PM	Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-24 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 (GlobeNewswire)
Jan-10-24 09:30AM	Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study (Zacks)
Jan-08-24 04:05PM	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 (GlobeNewswire) +11.29%
Jan-03-24 07:00AM	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 07:00AM	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 03:57PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.12%
05:48AM	Q3 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 07:00AM	Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-01-23 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 (GlobeNewswire) -5.23%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-06-23 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-23 06:58AM	Q2 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

FounderDr. Jean-Pierre Sommadossi Ph.D.

CFOMs. Andrea J. Corcoran J.D.

Chief Commercial OfficerMr. John F. Vavricka

Ph.D.Dr. Janet M. J. Hammond M.D.

Chief Medical OfficerDr. Maria Arantxa Horga M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lucidi Bruno	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	142,350	Jun 23 05:00 PM
BERGER FRANKLIN M	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	536,097	Jun 23 05:00 PM
DUNCAN BARBARA GAYLE	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	92,350	Jun 23 05:00 PM
Polsky Bruce	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	124,806	Jun 23 05:00 PM
Murphy Polly A.	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	121,745	Jun 23 05:00 PM
Adams Jerome M.	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	92,350	Jun 23 05:00 PM
Corcoran Andrea	See Remarks	Mar 11 '26	Option Exercise	1.24	60,000	74,400	823,576	Mar 13 06:00 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Feb 03 '26	Option Exercise	1.24	300,000	372,000	767,830	Feb 03 07:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVIR

Atea Pharmaceuticals Inc

Upgrade your Finviz experience